New York, May 27, 2026, 12:08 EDT
Accuray Inc. shares gave back an early push on Wednesday, slipping 0.9% to $0.3712 after touching $0.4982 in intraday trade, a sharp swing in a stock with a market value of about $44.6 million. More than 14.4 million shares had changed hands by late morning in New York.
The whipsaw matters because there was no fresh corporate release to trade on. Accuray’s investor site still showed its May 15 research pact with the University of Wisconsin-Madison and its May 6 quarterly results as the latest press releases, with no upcoming events listed; Nasdaq was in normal trading hours on Wednesday after its May 25 Memorial Day closure.
Investors instead were left to reprice the older problem: visibility. Accuray withdrew fiscal 2026 revenue and adjusted EBITDA guidance — adjusted EBITDA means profit before interest, taxes, depreciation and amortization, with certain items stripped out — after saying Middle East uncertainty was delaying shipments and service revenue. Fiscal third-quarter revenue fell 7% to $104.8 million, product orders dropped to $48.5 million from $71.2 million a year earlier, and backlog was 21% lower at $356.2 million; book-to-bill, orders divided by product revenue, fell to 1.0 from 1.2.
Chief Executive Steve LaNeve said the environment had created “significant unpredictability” and that it was “prudent to withdraw financial guidance.” That is the sentence traders are still working through.
The analyst tape has been thin but harsher since then. BTIG cut Accuray to Neutral from Buy on May 7, while Jefferies lowered the stock to Hold and cut its price target to 35 cents on May 12, according to Investing.com’s analyst-rating feed.
A May 22 SEC filing added another overhang. TCW entities reported beneficial ownership of 18.94 million Accuray shares, or about 13.7%, through warrants — rights to buy stock at set prices — tied to a delayed-draw term loan.
The bull case has not disappeared. Accuray and the University of Wisconsin School of Medicine and Public Health announced a 10-year collaboration to work on personalized cancer treatment using Accuray’s Stellar adaptive radiation therapy platform. LaNeve said the pact grounds its work in “real-world clinical practice,” while UW professor Zachary Morris said it could speed “translating research innovation.” PR Newswire
That matters because Accuray is small in a field with much larger competitors. Its latest annual filing says it competes in radiation therapy equipment with Varian, a Siemens Healthineers company, and Sweden’s Elekta, and notes that Varian has held the majority share in radiation therapy systems worldwide.
The broader tape was mixed. The QQQ exchange-traded fund, a proxy for large Nasdaq growth stocks, slipped 0.5%; the iShares U.S. Medical Devices ETF fell 1.6%; the Health Care Select Sector SPDR Fund rose 0.7%. Accuray’s move was less about the sector and more about its own balance-sheet and shipment story.
But the downside case is still plain. If delayed installations do not convert into revenue, Accuray may struggle to restore guidance with confidence, and any concern over future share supply from warrants could cap rallies in a stock already trading below 50 cents.
For now, the stock is not trading like a clean research-partnership story. It is trading like a company that must prove orders can turn into shipments, margins can recover, and the next forecast will hold.
